[Skip to Content]

Upstate Active Clinical Trials

Study Title:

ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Upstate Institutional Review Board (IRB) Number:

1601784

Study/Protocol ID:

ANBL1531

Study Phase:

III

Patient Age Group:

Children

Principal Investigator:

Philip Monteleone

Who can I contact for more information?

Name: Karen B Bilynsky
Phone: 315-464-7601
Email: bilynskk@upstate.edu

Return to Previous Page || Search Again

Top